BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16951268)

  • 1. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma.
    Brown RE; Zhang PL; Lun M; Zhu S; Pellitteri PK; Riefkohl W; Law A; Wood GC; Kennedy TL
    Ann Clin Lab Sci; 2006; 36(3):273-82. PubMed ID: 16951268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
    Feng W; Brown RE; Trung CD; Li W; Wang L; Khoury T; Alrawi S; Yao J; Xia K; Tan D
    Ann Clin Lab Sci; 2008; 38(3):195-209. PubMed ID: 18715846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
    Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
    Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma.
    Jackson-Bernitsas DG; Ichikawa H; Takada Y; Myers JN; Lin XL; Darnay BG; Chaturvedi MM; Aggarwal BB
    Oncogene; 2007 Mar; 26(10):1385-97. PubMed ID: 16953224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
    Dobashi Y; Suzuki S; Matsubara H; Kimura M; Endo S; Ooi A
    Cancer; 2009 Jan; 115(1):107-18. PubMed ID: 19090006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR and P70 S6 kinase expression in primary liver neoplasms.
    Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
    Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR as a potential therapeutic target for treatment of keloids and excessive scars.
    Ong CT; Khoo YT; Mukhopadhyay A; Do DV; Lim IJ; Aalami O; Phan TT
    Exp Dermatol; 2007 May; 16(5):394-404. PubMed ID: 17437482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs.
    Gordon IK; Ye F; Kent MS
    Am J Vet Res; 2008 Aug; 69(8):1079-84. PubMed ID: 18672974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma.
    Masuda M; Suzui M; Yasumatu R; Nakashima T; Kuratomi Y; Azuma K; Tomita K; Komiyama S; Weinstein IB
    Cancer Res; 2002 Jun; 62(12):3351-5. PubMed ID: 12067972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma.
    Baba HA; Wohlschlaeger J; Cicinnati VR; Hilgard P; Lang H; Sotiropoulos GC; Takeda A; Beckebaum S; Schmitz KJ
    Liver Int; 2009 Mar; 29(3):399-405. PubMed ID: 18492014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2.
    Chen SJ; Nakahara T; Takahara M; Kido M; Dugu L; Uchi H; Takeuchi S; Tu YT; Moroi Y; Furue M
    Br J Dermatol; 2009 Feb; 160(2):442-5. PubMed ID: 19016696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.
    Faried LS; Faried A; Kanuma T; Aoki H; Sano T; Nakazato T; Tamura T; Kuwano H; Minegishi T
    Mol Carcinog; 2008 Jun; 47(6):446-57. PubMed ID: 18058806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and activity of mTOR and its substrates in different cell cycle phases and in oral squamous cell carcinomas of different malignant grade.
    Liu Y; Hidayat S; Su WH; Deng X; Yu DH; Yu BZ
    Cell Biochem Funct; 2007; 25(1):45-53. PubMed ID: 16927414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy?
    Boone J; Ten Kate FJ; Offerhaus GJ; van Diest PJ; Rinkes IH; van Hillegersberg R
    J Clin Pathol; 2008 Aug; 61(8):909-13. PubMed ID: 18474542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
    Miyazawa M; Yasuda M; Fujita M; Kajiwara H; Hirabayashi K; Takekoshi S; Hirasawa T; Murakami M; Ogane N; Kiguchi K; Ishiwata I; Mikami M; Osamura RY
    Pathol Int; 2009 Jan; 59(1):19-27. PubMed ID: 19121088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphoproteomics demonstrates activation of mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation.
    Liu J; Brown RE
    Ann Clin Lab Sci; 2010; 40(3):211-7. PubMed ID: 20689131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.